

A Review On Medicinal Plants With Anti-Asthmatic Potential

Elango Kannan¹, Mumtha Logesh²

¹Faculty of Pharmacy, Karpagam Academy of Higher Education, Coimbatore, Tamilnadu, India 641021

²Assistant Professor, Department of Pharmacognosy, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamilnadu, India 643001

Abstract:

Asthma is a chronic disease that is rising worldwide with the highest prevalence in industrialized countries. Asthma affects about 300 million people worldwide and it has been estimated that a further 100 million will be affected by 2025. Since the ancient times, plants have been ideal sources of medicine. Current asthma therapy fails due to adverse effects; hence patients are seeking complementary and alternative medicine to treat their asthma/disease. Ayurveda and other ancient Indian literature speak briefly the use of plants in various human ailments. Studies conducted in the last few decades on the plants mentioned in ancient literature or used traditionally for asthma have shown antiasthmatic, antihistaminic and anti-allergic activity. This review reveals that some plants and their extract have antiasthmatic activity.

Keywords: Asthma, Medicinal Plants, Pathophysiology, In-vitro, In-vivo.

INTRODUCTION

1.3 Asthma

Asthma is a chronic inflammatory disorder of the airways associated with increased hyper-responsiveness, recurrent episodes of wheezing, breathlessness, chest tightness, and coughing because of reversible bronchoconstriction resulting from increased responsiveness of tracheobronchial tree to various stimuli.¹ This causes inflammation of the airway wall by increased number of inflammatory cells, most notably eosinophils, basophils, mast cells, macrophages, and certain types of lymphocytes^{2,4}. Asthma could be extrinsic and intrinsic depending upon the type of stimuli that triggers the attack.

✓ Extrinsic asthma is caused by a type of immune system response to inhaled allergens such as pollen, animal dander or dust mite particles.³

✓ Intrinsic asthma is caused by inhalation of chemicals such as cigarette smoke or cleaning agents, taking aspirin, chest infection, stress, cold air, exercise, food preservatives or a myriad of other factors⁵.

1.4 Epidemiology of asthma: an Overview

Asthma is world's most common long term disease conditions. According to the World Health Organization (WHO) over 339 million people around the world suffer from asthma, every day about 1,150 people die due to asthma as reported in 2018⁶. In India, an estimated 57,000 deaths were attributed to Asthma in 2004 and it was seen as one of the leading cause of morbidity and mortality in India^{7,8,9}.

Though effective screening, evaluation and management strategies for asthma are well established in high income countries, these strategies have not been fully implemented in India^{10,11}. Even though the medicines to treat asthma are available at affordable costs it benefits less than a percent¹².

1.5 Asthma-Global impact

Asthma is a non-reportable disease. Therefore, its global prevalence is difficult to determine since differences exist in regards to diagnostic protocols and access to healthcare. Furthermore, many asthma patients may be undiagnosed, as a recent study from Russia demonstrated that 6.9% of adults answering a questionnaire reported an asthma diagnosis, but 25.7% of the same population reported symptoms of asthma. According to Croissant's epidemiology section in the textbook Heterogeneity in Asthma published in 2014, approximately 4.3% of the world's population (300 million people) suffer from asthma. A recent study from Italy has confirmed that asthma is on the rise in countries outside of the United States, as a hike in asthma prevalence in Italy from 3.4 to 7.2% approximately in a period of 25 years. The Global Initiative for Asthma estimates that there will be an additional 100 million people with asthma around 2025¹³.

1.6 Prevalence of asthma

The prevalence of asthma has been estimated to range 3-38% in children and 2-12% in adults, being the commonest chronic disorder among children. In India, a recent Study on Epidemiology of Asthma, Respiratory Symptoms and Chronic Bronchitis (INSEARCH) done with 85,105 men and 84,470 women from 12 urban

and 11 rural sites estimated the prevalence of asthma in India to be 2.05% among those aged >15 years, with an estimated National burden of 18 million asthmatics ¹⁴.

1.7 Initiator components of allergic asthma


Allergy is an important undesirable side effect of immunity, which develops under certain conditions of hypersensitivity. Low molecular weight chemicals cause allergy by getting combined with an endogenous protein to form an antigenic complex. Based on the mechanism of immunological involvement there are 4 categories of allergic responses. Type I allergic reaction is the immediate hypersensitivity reaction. The allergen, immunoglobulin E (IgE) antibody, mast cell and its mediators (performed and newly released) are the major components of this type of allergic reaction.

An allergen binds to the Fab portion of the IgE antibody and the Fc portion binds to the mast cell receptor and basophils, which further leads to defragmentation of the mast cell and thus releasing the performed mediators such as histamine, leukotrienes and prostaglandins.

The newly formed mediators such as leukotrienes, prostaglandins, prostacyclin, lipoxins, thromboxanes are also responsible for the degranulation of the mast cells ¹⁴. The initial activation of the allergic reaction is responsible for the initial signs and symptoms in the respiratory system such as wheezing, running nose, edema etc, and the signs of the later stages are the airway remodelling and hyperplasia of the nasal tract etc. Anaphylaxis, allergic asthma, allergic rhinitis, allergic conjunctivitis and urticaria are some examples of Type I allergic diseases ¹⁵. Type II is antibody dependent cytotoxic reaction, haemolytic transfusion reaction and haemolytic disease of newborns are examples of this type. Type III is immune complex reaction, serum sickness and rheumatoid arthritis are examples of type III reaction. Type IV is cell mediated (delayed hypersensitivity) reaction. Tuberculin reactions, chronic asthma and contact dermatitis are examples of type IV allergic reaction.

1.8 Pathophysiology and therapeutic targets of asthma

Allergic asthma is a complex disease that is characterized by reversible airway obstruction, increased serum IgE level, airway remodelling, chronic eosinophilic airway inflammation, hypersecretion of mucus, airway hyperresponsiveness to bronchospasmogenic stimuli. These characteristic symptoms of asthma are mediated by many inflammatory cellular factors such as mast cells, eosinophils, neutrophils, macrophages and dendritic cells and also several other inflammatory mediators. Development of specific mediator-receptor antagonists or inhibitor of mediator synthesis may give the novel therapeutic regimen to counter asthma ¹⁶. Some important cells/molecules that contribute to the pathogenesis of asthma are






Figure1:Pathogenesis of Asthma

RESULT:

Table 1: Medicinal plants with anti-asthmatic effect

S.No	Plant material	Family	Parts	Invitro studies	Invivo studies	Ref
1	<i>Acorus calamus</i>	Acoraceae	Leaves Roots Rhizomes	Histamine induced contractile response in isolated guinea pig ileum Histamine induced bronchospasm in guinea pig isolated Guinea pig ileum preparation	No Data Histamine Aerosol induced bronchoconstriction in Guinea pigs	17 18 19
2	<i>Aerva lanta</i>	Amaranthaceae	Whole plant Aerial parts	Not performed Isolated goat tracheal chain preparation model	Ovalbumin induced allergic asthmatic mice Clonidine-induced catalepsy and Mast cell degranulation in mice	20 21
3	<i>Ailanthus excels</i>	Simaroubaceae	Stem bark	Isolated Guinea pig ileum preparation	Histamine induced bronchoconstriction in Guinea pigs	22

			Leaves	Isolated goat trachea chain preparation	Clonidine induced catalepsy in mice and Clonidine-induced mast cell degranulation	23
4	<i>Alternanthera sessilis</i>	Amaranthaceae	Stem	Not performed	Guinea pigs model	24
5	<i>Azima tetracantha</i>	Salvadoraceae	Leaves	Mast cell stabilization assay	No Data	25
6	<i>Bacopa monnieri</i>	Plantaginaceae	Leaves and stem	Not performed	OVA-induced airway inflammation in BALB/C mice.	26
7	<i>Boerhaavia diffusa</i>	Nyctaginaceae	Roots	Isolated Goat tracheal chain preparation	Histamine induced Bronchoconstriction in Guinea pig	27
8	<i>Calotropis gigantean</i>	Apocynaceae	Flowers	No Data	Histamine and acetylcholine induced Bronchoconstriction in Guinea pig	28
			Leaves	No Data	Histamine induced Bronchospasm in Guinea pig Acetylcholine and Histamine induced bronchospasm in guinea pigs,	29
			Roots	Isolated Guinea pig ileum preparation	Haloperidol induced catalepsy and passive paw anaphylaxis in rats	30
9	<i>Calotropis procera</i>	Asclepiadaceae	Root	isolated guinea pig ileum preparation	guinea pig tracheal chain	31
			Leaves	Not performed	Chlorine induced asthma in Albino mice	32
10	<i>Clerodendron phlomidis</i>	Lamiaceae	Leaves	Isolated goat tracheal chain	Milk- induced eosinophilia, mast cell degranulation and capillary permeability in mice.	33
11	<i>Cynodon dactylon</i>	Poaceae	Leaves	isolated guinea pig ileum preparation and isolated guinea pig tracheal chain preparation	Histamine and acetylcholine induced bronchospasm in guinea pigs and milk induced eosinophilia in mice model	34
12	<i>Eclipta prostrata</i>	Asteraceae	Whole plant	Not performed	murine model of asthma	35
13	<i>Elaeagnus pungens</i>	Elaeagnaceae	Leaves	Not performed	Histamine and acetylcholine induced Bronchoconstriction in Guinea pig	36
14	<i>Hemidesmus indicus</i>	Asclepiadaceae	Roots	Not performed	Isolated goat trachea chain preparation Clonidine induced catalepsy in mice	37
15	<i>Ipomoea aquatic</i>	Convolvulaceae	Leaves	Not performed	OVA induced murine model.	38
16	<i>Justicia procumbens</i>		Aerial parts	Not performed	Spleen Cell Culture and Cytokine Assay OVA induced murine model.	39
17	<i>Mangifera indica</i>	Anacardiaceae	Bark	Not performed	Airway inflammation and Th2 cytokines in murine model	40
18	<i>Ocimum basilicum</i>	Lamiaceae	Leaves	Not performed	Ovalbumin-induced rat model Ovalbumin-induced rat model	41
			Seeds	Not performed		42

19	Pothos scandens	Araceae	Aerial parts	-	Mast cell stabilization	43
20	Vitex negunda	Lamiaceae	Leaves	Not performed	Murine model of OVA-LPS induced allergic asthma	44
			Leaves	Not performed	Heterologous passive cutaneous anaphylaxis model and Egg-albumin induced asthma in guinea pigs	45

DISCUSSION:

Asthma, a chronic respiratory condition characterized by airway inflammation and bronchoconstriction, significantly impacts the quality of life of millions worldwide. Despite the availability of conventional treatments, there is a growing interest in alternative therapies, particularly the use of medicinal plants known for their antiasthmatic properties.

Acorus calamus, commonly known as sweet flag, has been traditionally used for its anti-inflammatory and bronchodilatory effects. The rhizomes contain bioactive compounds such as α -asarone and β -asarone, which exhibit significant antispasmodic and anti-asthmatic properties. Studies have shown that these compounds can reduce bronchial constriction and inflammation, thereby improving airflow and reducing asthma symptoms.^{17,19}

The leaves and bark of *Ailanthus excelsa* possess anti-inflammatory and bronchodilatory properties. The presence of quassinoids and alkaloids contributes to its efficacy in treating asthma. These compounds have been demonstrated to inhibit the release of histamine and other inflammatory mediators, which are pivotal in the pathophysiology of asthma. *Azima tetracantha*, known for its anti-inflammatory and immunomodulatory properties, contains bioactive compounds such as lignans and flavonoids. These compounds help in reducing airway inflammation and modulating immune responses, which are crucial in controlling asthma exacerbations.²² *Boerhaavia diffusa* has a long history of use in Ayurvedic medicine for respiratory ailments. Its anti-asthmatic activity is attributed to its bronchodilatory, anti-inflammatory, and immunomodulatory effects.

The plant contains bioactive compounds like boeravinones and punarnavoside, which help in reducing bronchial inflammation and improving lung function. The latex and leaves of *Calotropis gigantea* are rich in compounds such as calotropin and uscharin, which have shown significant bronchodilatory and anti-inflammatory effects. These compounds help in relaxing the bronchial muscles and reducing airway inflammation, thereby alleviating asthma symptoms.²⁶ *Clerodendron phlomidis* possesses anti-inflammatory and bronchodilatory properties, making it a valuable medicinal plant in asthma management. The plant contains diterpenes and flavonoids, which help in reducing bronchial hyperresponsiveness and airway inflammation.

Elaeagnus pungens aid in reducing bronchial inflammation and spasms, thereby improving respiratory function in asthma patients.²⁸ *Ipomoea aquatica*, commonly known as water spinach, has been traditionally used for its anti-inflammatory and bronchodilatory effects. The plant contains bioactive compounds such as alkaloids and flavonoids, which help in reducing airway inflammation and bronchoconstriction.²⁹ The presence of lignans and flavonoids in *Justicia procumbens* contributes to its effectiveness in reducing airway inflammation and improving respiratory function in asthma patients.³⁰ *Mangifera indica*, commonly known as mango, has leaves and bark that exhibit significant anti-inflammatory and bronchodilatory properties.

The presence of mangiferin and other polyphenols helps in reducing bronchial inflammation and improving lung function. *Pothos scandens*, known for its anti-inflammatory and bronchodilatory properties, contains bioactive compounds such as flavonoids and saponins. These compounds help in reducing airway inflammation and bronchoconstriction, thereby improving respiratory function in asthma patients.

The use of medicinal plants in the management of asthma offers a promising alternative or complementary therapy to conventional treatments. The antiasthmatic activity of these plants is primarily due to their anti-inflammatory, bronchodilatory, and immunomodulatory properties. Further research and clinical trials are essential to validate the efficacy and safety of these medicinal plants, ensuring their integration into mainstream asthma management protocols. These medicinal plants highlights the importance of exploring natural remedies in the quest for effective asthma treatments.

CONCLUSION:

The integration of these medicinal plants into asthma management strategies offers a complementary approach to conventional therapies, potentially enhancing treatment efficacy and reducing side effects. However, it is crucial to acknowledge the need for rigorous clinical trials to establish standardized dosages, safety profiles, and long-term efficacy of these herbal treatments. While the initial findings are encouraging, healthcare professionals should guide the use of these medicinal plants to prevent adverse interactions with conventional asthma medications. Future research should focus on exploring the synergistic effects of these plants with standard treatments, understanding their molecular mechanisms in greater detail, and developing optimized formulations for clinical use. In conclusion, medicinal plants hold a valuable place in the arsenal against asthma, providing hope for more holistic and effective management of this chronic respiratory condition. Their incorporation into mainstream medical practice could revolutionize asthma care, but it must be approached with caution, scientific rigor, and an emphasis on patient safety.

CONFLICT OF INTEREST:

The authors have no conflicts of interest regarding this investigation.

REFERENCE:

1. Undem BJ. Pharmacotherapy of asthma. Goodman & Gilman. The Pharmacological Basis of Therapeutics. 11th ed. New York: McGrawHill. 2006:717-36.
2. Network GA. The global asthma report 2018. 2018.
3. Ganesh Kumar S, Premarajan KC, Sonali Sarkar SK, Sahana A, Abhishek A, Aprajita R. Prevalence and factors associated with asthma among school children in rural Puducherry, India. *Current pediatric research*. 2012. doi: 10.4103/0976-9668.127289
4. Krishnakumar A. The silent tormentor. *Frontline*. 2003 Aug;20(17):16-29.
5. Mitchell EA. Is current treatment increasing asthma mortality and morbidity?. *Thorax*. 1989 Feb;44(2):81. doi: 10.1136/thx.44.2.81
6. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2012.
7. Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. *Allergy*. 2004 May;59(5):469-78. DOI: 10.1111/j.1398-9995.2004.00526.x
8. Sullivan S, Elixhauser A, Buist AS, Luce BR, Eisenberg J, Weiss KB. National Asthma Education and Prevention Program working group report on the cost effectiveness of asthma care. *Am J Respir Crit Care Med*. 1996 Sep 1;154(3 Pt 2):S84-95. DOI: 10.1164/ajrccm/154.3_Pt_2.S84
9. Loftus PA, Wise SK. Epidemiology of asthma. *Current opinion in otolaryngology & head and neck surgery*. 2016 Jun 1;24(3):245-9. DOI: 10.1097/MOO.0000000000000262
10. Koul PA, Patel D. Indian guidelines for asthma: Adherence is the key. *Lung India: official organ of Indian Chest Society*. 2015 Apr;32(Suppl 1):S1. doi: 10.4103/0970-2113.154511
11. Jindal SK, Aggarwal AN, Gupta D, Agarwal R, Kumar R, Kaur T, Chaudhry K, Shah B. Indian study on epidemiology of asthma, respiratory symptoms and chronic bronchitis in adults (INSEARCH). *The International journal of tuberculosis and lung disease*. 2012 Sep 1;16(9):1270-7. DOI: 10.5588/ijtld.12.0005
12. Barnes PJ. The role of inflammation and anti-inflammatory medication in asthma. *Respiratory medicine*. 2002 Feb 1;96:S9-15. doi.org/10.1053/rmed.2001.1232
13. Van der Heijden M, Kraneveld A, Redegeld F. Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases. *European journal of pharmacology*. 2006 Mar 8;533(1-3):319-26. Doi: 10.1016/j.ejphar.2005.12.065
14. Barnes PJ. The role of inflammation and anti-inflammatory medication in asthma. *Respiratory medicine*. 2002 Feb 1;96:S9-15. DOI:10.1053/rmed.2001.1232
15. Van der Heijden M, Kraneveld A, Redegeld F. Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases. *European journal of pharmacology*. 2006 Mar 8;533(1-3):319-26.
16. Heijink IH, Van Oosterhout AJ. Targeting T cells for asthma. *Current opinion in pharmacology*. 2005 Jun 1;5(3):227-31. DOI: 10.1016/j.coph.2005.04.002
17. Vijayapandia P, Annabathina V, SivaNagaSrikanth B, Manjunath V, Boggavarapu P, RajendraPrasad K, Kumarappan CT. In vitro anticholinergic and antihistaminic activities of *Acorus calamus* Linn. leaves extracts. *African Journal of Traditional, Complementary and Alternative Medicines*. 2013;10(1):95-101.
18. Dubey S. ANTI-ASTHMATIC ACTIVE COMPO ACORUS CALAM. *Journal Homepage: http://ijmr.net*. in. 2019 Jul;7(07).
19. Saxena P, Saxena P. In-vitro and in-vivo evaluation of anti asthmatic activity of rhizomes extract of *Acorus calamus* (Linn.) in guinea pigs. *Research Journal of Pharmaceutical Sciences* ISSN. 2014;2319:555X.
20. Sharif M, Anjum I, Shabbir A, Mushtaq MN. Immunomodulatory and anti-inflammatory effects of *Aerva lanata* in ovalbumin induced allergic asthmatic mice. *Journal of Ethnopharmacology*. 2022; 289:115087.
21. Kumar D, Bhujbal SS, Deoda RS, Mudgade SC. In-vitro and in-vivo antiasthmatic studies of *Ailanthus excelsa* Roxb. on guinea pigs. *Journal of scientific research*. 2010;2(1):196-202. DOI:10.3329/jsr.v2i1.2740
22. Kumar D, Bhujbal SS, Deoda RS, Mudgade SC. In-vitro and in-vivo antiasthmatic studies of *Ailanthus excelsa* Roxb. on guinea pigs. *Journal of scientific research*. 2010; 2: 196-202.
23. Kumar D, Bhat ZA, Singh P, Khatanglakar V, Bhujbal SS. Antiasthmatic and antiallergic potential of methanolic extract of leaves of *Ailanthus excelsa*. *Revista Brasileira de Farmacognosia*. 2011;21:139-45.

24. Vani M, Rahaman SA, Rani AP. In vivo antiasthmatic studies & phytochemical characterization on the stem extracts of *Alternanthera sessilis* L. using Guinea pigs model. *Journal of Entomology and Zoology Studies*. 2017; 5: 1160-71.
25. Hepsibha TB. Validation of ameliorative efficacy of *Azima tetracantha* leaf extracts on asthma through mast cell stabilization assay. *J Chem Pharm Res*. 2015;7:907-14.
26. Suralkar AA, Verma AK, Kamble RD, Tayade GV. Pharmacological evaluation of anti-histaminic activity of *Boerhaavia diffusa*. *Int. J. Adv. Pharm. Biol. Chem*. 2012;1(4):503-7.
27. K Soni K, Shrivastava PN, Jones T, J Mahady L, Patel U, Mukherjee P et al. Extracts of *Bacopa monnieri* (L) Pennell Down-Regulate the Expression of Leukotriene C4 Synthase mRNA in HL-60 Cells and Suppress OVAInduced Inflammation in BALB/c Mice. *Current Bioactive Compounds*. 2014; 10: 21-30.
28. Jaliwala YA, Neha C, Bhatt NK, Panda PK, Mohanti PK. Pharmacological evaluation of anti-tussive, anti-asthmatic and expectorant activities of *Calotropis gigantea* R. Br. in experimental animals. *Journal of Pharmacy Research*. 2011 Oct;4(10):3383-5. DOI:10.37191/Mapsci-2582-4937-4(2)-028
29. Afreen A., Kashyap P., Sawarkar H., Deshmukh V., Upadhyay A. and Pal S., In- vitro and In- vivo Models for Evaluation of Anti-Asthmatic Activity: A Review, *International Journal of Herbal Drug Research*, I(1), 19-27(2011).
30. Thosar A, Mayee R and Kondapure A. Evaluation of antiasthmatic activity of *calotropis gigantea* roots. *Asian J Pharm Clin Res*. 2011;4(2):3335. DOI: <https://doi.org/10.18203/2319-2003.ijbcp20212375>
31. Aliyu IM, Zezi AU, Magaji MG, Abdu-Aguye I, Ibrahim ZY, Atiku I et al. Anti-histaminic and bronchodilatory activities of aqueous and methanol extracts of *Calotropis procera* (Ait) R. Br. root bark on allergic asthma in rodents. *Journal of Pharmacy & Bioresources*. 2017; 14: 128-46.
32. Fathima A. Effect Of Methanolic Extract *Calotropis Procer* (Ait) R. Br Against Chlorine Induced Asthma In Mice.
33. Vadnere G, Somani R, Singhai AK. Studies on antiasthmatic activity of aqueous extract of *Clerodendron phlomidis*. *Journal of Pharmacy and Pharmacology*. 2006 Jan 1;58(10):164.
34. Singh R, Mishra RK, Chaubey N. Evaluation Of Anti-Asthmatic Activity Of Ethanolic Extract Of *Cynodon Dactylon* Leaves. *Journal of Advanced Scientific Research*. 2021; 12.
35. de Freitas Morel LJ, de Azevedo BC, Carmona F, Contini SH, Teles AM, Ramalho FS et al. A standardized methanol extract of *Eclipta prostrata* (L.) L.(Asteraceae) reduces bronchial hyperresponsiveness and production of Th2 cytokines in a murine model of asthma. *Journal of Ethnopharmacology*. 2017; 198: 226-34.
36. Ge Y, Liu J, Su D. In vivo evaluation of the anti-asthmatic, antitussive and expectorant activities of extract and fractions from *Elaeagnus pungens* leaf. *Journal of ethnopharmacology*. 2009 Dec 10;126(3):538-42. doi: 10.1155/2015/428208
37. Bhujbal SS, Kumar D, Deoda RS, Deore TK, Patil MJ. Antiasthmatic Activity Of Roots Of *Hemidesmus indicus* R. Br. *Pharmacology online*. 2009; 1: 209-16.
38. Gupta A, Sharma PK, Sharma R, Ganesan K, Jain S. Preparation And Assessment Of Antiasthmatic Activity Of Different Extract Of *Ipomoea Aquatica*, *Cinnamomum Zeylanicum*, And *Piper Longum* Containing Polyherbal Formulation.
39. Youm J, Lee H, Chang HB, Jeon J, Yoon MH, Woo JY, Choi MS, Hwang Y, Seong S, Na K, Yoon J. *Justicia procumbens* extract (DW2008) selectively suppresses th2 cytokines in splenocytes and ameliorates ovalbumin-induced airway inflammation in a mouse model of asthma. *Biological and Pharmaceutical Bulletin*. 2017 Sep 1;40(9):1416-22. Doi: 10.1248/bpb.b17-00179
40. Rivera DG, Hernández I, Merino N, Luque Y, Álvarez A, Martín Y, Amador A, Nuevas L, Delgado R. *Mangifera indica* L. extract (Vimang) and mangiferin reduce the airway inflammation and Th2 cytokines in murine model of allergic asthma. *Journal of Pharmacy and Pharmacology*. 2011 Oct;63(10):1336-45. Doi: 10.1111/j.2042-7158.2011.01328.x
41. Eftekhari N, Moghimi A, Mohammadian Roshan N, Saadat S, Boskabady MH. Immunomodulatory and anti-inflammatory effects of hydro-ethanolic extract of *Ocimum basilicum* leaves and its effect on lung pathological changes in an ovalbumin-induced rat model of asthma. *BMC complementary and alternative medicine*. 2019; 19: 1-1.
42. Athari SM, Nasab EM, Athari SS. Study effect of *Ocimum basilicum* seeds on mucus production and cytokine gene expression in allergic asthma mice model. *Revue Française d'Allergologie*. 2018; 58: 489-93.
43. Gupta S, Duraiswamy B, Satishkumar MN. Peritoneal mast cell stabilization potential of *Pothos scandens* L. *Indian journal of pharmacology*. 2013 Jan;45(1):83. doi: 10.4103/0253-7613.106442
44. Tirpude NV, Sharma A, Joshi R, Kumari M, Acharya V. *Vitex negundo* Linn. extract alleviates inflammatory aggravation and lung injury by modulating AMPK/PI3K/Akt/p38-NF- κ B and TGF- β /Smad/Bcl2/caspase/LC3 cascade and macrophages activation in murine model of OVA-LPS induced allergic asthma. *Journal of Ethnopharmacology*. 2021; 271: 113894.
45. Patel J, Shah S, Deshpande S, Shah G. Evaluation of the antiasthmatic activity of leaves of *Vitex negundo*. *Asian J Pharm Clin Res*. 2009; 2: 81-6.